Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at Hsbc Global Res

Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA - Free Report) to a strong-buy rating in a research note published on Monday,Zacks.com reports.

Several other research analysts have also recently issued reports on the stock. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Up 3.8 %

Teva Pharmaceutical Industries stock traded up $0.60 during mid-day trading on Monday, hitting $16.22. The company's stock had a trading volume of 11,919,719 shares, compared to its average volume of 9,977,348. The business has a 50 day moving average price of $15.11 and a 200-day moving average price of $17.49. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market cap of $18.39 billion, a price-to-earnings ratio of -11.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 12.8% in the 1st quarter. Victory Capital Management Inc. now owns 3,410,142 shares of the company's stock worth $52,414,000 after buying an additional 386,668 shares during the last quarter. Burford Brothers Inc. grew its stake in shares of Teva Pharmaceutical Industries by 2.1% in the first quarter. Burford Brothers Inc. now owns 155,876 shares of the company's stock worth $2,396,000 after acquiring an additional 3,189 shares during the last quarter. Hara Capital LLC increased its holdings in shares of Teva Pharmaceutical Industries by 4.7% during the first quarter. Hara Capital LLC now owns 31,814 shares of the company's stock valued at $489,000 after acquiring an additional 1,434 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after purchasing an additional 22,044,407 shares during the last quarter. Finally, IFM Investors Pty Ltd boosted its stake in Teva Pharmaceutical Industries by 11.6% in the 1st quarter. IFM Investors Pty Ltd now owns 231,028 shares of the company's stock worth $3,551,000 after purchasing an additional 23,941 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.